anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-21. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
== Commercial situation == As of 2017, Cytiva holds patents around three-column periodic counter-current chromatography: this technology is used in their Äkta PCC instrument. Likewise, ChromaCon holds patents for an optimized two-column version (CaptureSMB). CaptureSMB is used in ChromaCon's Contichrom CUBE and under license in YMC's Ecoprime Twin systems. Additional manufacturers of systems capable of periodic counter-current chromatography include Novasep and Pall.
DNA sequence data shows that the mummies had Haplogroup R1a (Y-DNA) characteristic of western Eurasia in the area of East-Central Europe, Central Asia and the Indus Valley. This has created a stir in the Turkic-speaking Uighur population of the region, who claim the area has always belonged to their culture, while it was not until the 10th century that Uighurs are said by scholars to have moved to the region from Central Asia. American Sinologist Victor H. Mair claims that "the earliest mummies in the Tarim Basin were exclusively Caucasoid, or Europoid" with "east Asian migrants arriving in the eastern portions of the Tarim Basin around 3,000 years ago", while Mair also notes that it was not until 842 that the Uighur peoples settled in the area. Other mummified remains have been recovered from around the Tarim Basin at sites including Qäwrighul, Yanghai, Shengjindian, Shanpula (Sampul), Zaghunluq, and Qizilchoqa.
== Biography == Peter Joseph Moloney and his three sisters, whose father died in 1897, were raised in Powassan by their widowed mother. The four siblings were the grandchildren of Irish Catholics who left Ireland during the Great Famine of Ireland and settled in Warminster, Southern Ontario. He received secondary education at the preparatory school of St. Michael's College, Toronto. He earned a bachelor's degree from the University of Toronto in 1912 and a master's degree with thesis Rate of Solution and Precipitation of Gypsum in chemistry in 1915. During a stay at the University of California at Berkeley for the academic year 1915–1916, he met Angelina Cecilia Chapman. They married in Berkeley on July 6, 1916. Moloney worked between 1917 and 1919 at the Department of Agriculture in Ottawa in food chemistry. From 1919 Moloney worked as a research assistant for Connaught Laboratories, a vaccine manufacturer that emerged from the University of Toronto and now belongs to Sanofi. While working for Connaught Laboratories he studied at the University of Toronto, where his mentor was John G. FitzGerald. After acquiring a Ph.D. with thesis On the Purification of Insulin in 1924 from the University of Toronto, Moloney was in the working group of Charles Best and Frederick Banting from 1921 with the purification of insulin to make it clinically usable, which was achieved for the first time in 1922.
== Non-enzymatic processes == Protein backbones are very stable in water at neutral pH and room temperature, although the rate of hydrolysis of different peptide bonds can vary. The half-life of a peptide bond under normal conditions can range from 7 years to 350 years, even higher for peptides protected by modified terminus or within the protein interior. The rate of hydrolysis however can be significantly increased by extremes of pH and heat. Spontaneous cleavage of proteins may also involve catalysis by zinc on serine and threonine. Strong mineral acids can readily hydrolyse the peptide bonds in a protein (acid hydrolysis). The standard way to hydrolyze a protein or peptide into its constituent amino acids for analysis is to heat it to 105 °C for around 24 hours in 6M hydrochloric acid. However, some proteins are resistant to acid hydrolysis. One well-known example is ribonuclease A, which can be purified by treating crude extracts with hot sulfuric acid so that other proteins become degraded while ribonuclease A is left intact. Certain chemicals cause proteolysis only after specific residues, and these can be used to selectively break down a protein into smaller polypeptides for laboratory analysis. For example, cyanogen bromide cleaves the peptide bond after a methionine. Similar methods may be used to specifically cleave tryptophanyl, aspartyl, cysteinyl, and asparaginyl peptide bonds. Acids such as trifluoroacetic acid and formic acid may be used for cleavage. Like other biomolecules, proteins can also be broken down by high heat alone.
Sources: en.wikipedia.org
Reports from clinicians based at other Italian institutions detailed significantly fewer leucotomy operations. Experimental modifications of Moniz's operation were introduced with little delay by Italian medical practitioners. Most notably, in 1937 Amarro Fiamberti, the medical director of a psychiatric institution in Varese, first devised the transorbital procedure whereby the frontal lobes were accessed through the eye sockets. Fiamberti's method was to puncture the thin layer of orbital bone at the top of the socket and then inject alcohol or formalin into the white matter of the frontal lobes through this aperture. Using this method, while sometimes substituting a leucotome for a hypodermic needle, it is estimated that he leucotomised about 100 patients in the period up to the outbreak of World War II. Fiamberti's innovation of Moniz's method would later prove inspirational for Walter Freeman's development of transorbital lobotomy.
== Types of cells == Macrophages: Supported by a network of connective tissue. Understood as the Reticuloendothelial System, the RES allows microglial differential in the CNS, pulmonary alveolar macrophages, tissue histiocytes, Kupffler Hepatic macrophages, Glomerular Mesangial Proliferation and unnamed Splenic expression of wandering macrophages. Sharing of iron storage remains an essential mystery. Lymphocytes: These are cells responsible for immune responses that circulate in the blood. Normally, only small numbers are found in the CTs throughout the body. The number increases dramatically at certain sites of tissue inflammation. They are also very numerous in the lamina propria of the respiratory and gastrointestinal tracts, where they are involved in immunosurveillance. The lamina propria is a layer of loose CT lying immediately beneath the epithelium. Plasma cells: Plasma cells are derived from B-lymphocytes and produce antibodies against a specific antigen. They have a limited migratory ability and a short life. Neutrophils: Neutrophils are white blood cells that act as phagocytes in the early stages of acute inflammation. Eosinophils: Eosinophils are white blood cells that are found in the lamina propria of the GI tract, and at sites of allergic reaction and parasitic infection. Basophils: Basophils are white blood cells that are similar to mast cells in having vasoactive agents released in response to an allergen. Monocytes: Monocytes are white blood cells that will give rise to all the phagocytes of the mononuclear phagocytic system (see Ross et al., pg.
In 1959, Ivy began producing his own version of the drug under the name "Carcalon". On October 28, 1964, the Durovics, Ivy and the Krebiozen Research Foundation were indicted for introducing mislabeled drugs into interstate commerce in violation of the Food, Drug and Cosmetic Act. After a 9-month trial, the case ended with a hung jury and they were acquitted. Soon afterwards, Durovic was indicted for tax evasion and fled the United States.
== History == After World War I, the German government sought alternatives to quinine as an anti-malarial. Chloroquine, a synthetic analogue with the same mechanism of action was discovered in 1934, by Hans Andersag and coworkers at the Bayer laboratories. This was introduced into clinical practice in 1947 for the prophylactic treatment of malaria. Researchers subsequently attempted to discover structural analogs with superior properties and one of these was hydroxychloroquine.
=== Chronic compression === Like acute compression, chronic compression starts with the impairment of the microcirculatory environment. Studies on pressure have identified a "critical pressure level", above which the nerve is significantly impaired. This pressure level is 30mmHg below diastolic or 45mmHg below systolic blood pressure. Interestingly, patients with higher blood pressure require larger compressive forces to interrupt the microcirculatory environment.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.